Zai Lab (Zai Lab) Cash-to-Debt : 53.23 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Zai Lab Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zai Lab's cash to debt ratio for the quarter that ended in Dec. 2023 was 53.23.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Zai Lab could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Zai Lab's Cash-to-Debt or its related term are showing as below:

ZLAB' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.67 Med: 72.28 Max: No Debt
Current: 53.23

During the past 9 years, Zai Lab's highest Cash to Debt Ratio was No Debt. The lowest was 12.67. And the median was 72.28.

ZLAB's Cash-to-Debt is ranked better than
73.29% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs ZLAB: 53.23

Zai Lab Cash-to-Debt Historical Data

The historical data trend for Zai Lab's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zai Lab Cash-to-Debt Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

12.67

63.81

90.68

49.45

53.23

Zai Lab Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															49.45	45.84	45.90	49.14	53.23

Competitive Comparison of Zai Lab's Cash-to-Debt

For the Biotechnology subindustry, Zai Lab's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zai Lab's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zai Lab's Cash-to-Debt falls into.

Zai Lab Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zai Lab's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	806.451	/	(7.104	+	8.047)
	=	53.23

Zai Lab's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	806.451	/	(7.104	+	8.047)
	=	53.23

Zai Lab (NAS:ZLAB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zai Lab Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zai Lab's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zai Lab (Zai Lab) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (NAS:ZLAB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ZLAB:Mexico 09688:Hong Kong 1ZLB:Germany 1ZLB:Germany 1ZL:Germany 1ZL:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Executives

Harald Reinhart	officer: Chief Medical Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Edmondson Frazor Titus Iii	officer: Chief Legal Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Ying Du	director, officer: Chairwoman & CEO	C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210
Rafael Amado	officer: See Remarks	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Joshua L Smiley	officer: Chief Operating Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Yajing Chen	officer: Chief Financial Officer	314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Peter Wirth	director	37 HANCOCK STREET, BOSTON MA 02114
John D Diekman	director	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Richard Gaynor	director	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Tao Fu	director, officer: President & COO	3175 HANOVER STREET, PALO ALTO CA 94304
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Cho William Ki Chul	officer: Chief Financial Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Kai-xian Chen	director	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210